Gamma-aminobutyric acid type A receptor beta-2 subunit (GABA_A_ receptor beta-2 subunit (GABRB2))

The **gamma-aminobutyric acid type A receptor beta-2 subunit** is one of several subunits that combine to form the GABA_A_ receptor, a major ligand-gated chloride ion channel in the central nervous system encoded by the GABRB2 gene[1][2][3]. GABA_A_ receptors are heteropentameric complexes composed typically of two α, two β, and one γ subunits, with the α1β2γ2 composition being the most abundant in the brain[1][3][7]. The beta-2 subunit, along with others, forms the chloride ion channel pore and participates in GABA (the main inhibitory neurotransmitter in the CNS) recognition and signaling[2][3][8]. The GABA_A_ receptor beta-2 subunit is crucial for mediating the effects of several important therapeutic drug classes, such as benzodiazepines (anxiolytics, hypnotics), barbiturates, Z-drugs (hypnotics), intravenous anesthetics (e.g., propofol, etomidate), neurosteroids, and ethanol[7][8]. Dysregulation or genetic variation of GABRB2 is implicated in various neurological and psychiatric diseases including epilepsy, schizophrenia, and intellectual disability. GABA_A_ receptor modulators targeting this subunit are associated with risks such as sedation, tolerance, dependence, and CNS depression, highlighting the importance of tight functional regulation and careful therapeutic monitoring[2][7].

Other names

GABA_A_ receptor β2 subunitGABRB2gamma-aminobutyric acid receptor subunit beta-2

Positive allosteric modulation (benzodiazepines, barbiturates, neurosteroids enhance GABAergic transmission); Direct agonist binding (GABA) leading to chloride influx and neuronal inhibition; Negative allosteric modulation (certain inverse agonists/antagonists reduce GABAergic transmission); Some anesthetics can directly activate or modulate the receptor independent of GABA binding.